Celsion rises on positive ThermoDox data

|About: Celsion Corporation (CLSN)|By:, SA News Editor

Celsion (CLSN) shares +4.2% after saying that the latest data from a Phase III study of its ThermoDox treatment for hepatocellular carcinoma (HCC), the most common type of liver cancer, continues to show that the product improves progression-free and overall survival rates.

ThermoDox significantly improves the latter in patients with single lesions if they undergo Radiofrequency Ablation (RFA) for 45 minutes or more. Ablation is the removal of biological tissue. (PR)